Free Trial

Palvella Therapeutics (PVLA) Stock Price, News & Analysis

Palvella Therapeutics logo
$56.69 -2.02 (-3.44%)
As of 04:00 PM Eastern

About Palvella Therapeutics Stock (NASDAQ:PVLA)

Advanced

Key Stats

Today's Range
$56.56
$59.60
50-Day Range
$28.42
$59.73
52-Week Range
$11.17
$63.12
Volume
262,507 shs
Average Volume
127,118 shs
Market Capitalization
$626.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.91
Consensus Rating
Buy

Company Overview

Palvella Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

PVLA MarketRank™: 

Palvella Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 747th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Palvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Palvella Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Palvella Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Palvella Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Palvella Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Palvella Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Palvella Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Palvella Therapeutics has a P/B Ratio of 10.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Palvella Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.50% of the float of Palvella Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Palvella Therapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

  • Dividend Yield

    Palvella Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Palvella Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.50% of the float of Palvella Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Palvella Therapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

  • News Sentiment

    Palvella Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Palvella Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for PVLA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Palvella Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.50% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Palvella Therapeutics' insider trading history.
Receive PVLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PVLA Stock News Headlines

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM
Recession Risk: 90% — Are Your Savings Ready?
Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.tc pixel
See More Headlines

PVLA Stock Analysis - Frequently Asked Questions

Palvella Therapeutics' stock was trading at $12.00 at the beginning of 2025. Since then, PVLA shares have increased by 372.4% and is now trading at $56.69.

Palvella Therapeutics, Inc. (NASDAQ:PVLA) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.08.
Read the conference call transcript
.

Palvella Therapeutics' top institutional shareholders include Frazier Life Sciences Management L.P. (6.53%), Adams Street Partners LLC (2.70%), Geode Capital Management LLC (1.57%) and Clio Asset Management LLC (0.83%).
View institutional ownership trends
.

Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2025
Today
9/23/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PVLA
Previous Symbol
NASDAQ:PVLA
CIK
1583648
Employees
N/A
Year Founded
2015

Price Target and Rating

High Price Target
$90.00
Low Price Target
$44.00
Potential Upside/Downside
+7.4%
Consensus Rating
Buy
Rating Score (0-4)
3.08
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($12.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$17.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-62.30%
Return on Assets
-43.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.67
Quick Ratio
7.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.58 per share
Price / Book
10.16

Miscellaneous

Outstanding Shares
11,060,000
Free Float
8,793,000
Market Cap
$626.99 million
Optionable
N/A
Beta
-0.04

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PVLA) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners